Effects of PRK 124 Lotion in Acne Rosacea

This study has been completed.
Sponsor:
Collaborator:
SenetekPLC
Information provided by (Responsible Party):
Christopher Zachary, University of California, Irvine
ClinicalTrials.gov Identifier:
NCT00580723
First received: December 21, 2007
Last updated: December 16, 2013
Last verified: December 2013
  Purpose

The purpose of this open-label study is to determine the tolerance and efficacy of twice-daily application of PRK 124 (Pyratine-6)(0.125%) moisturizing lotion for improving the signs and symptoms of mild to moderate facial rosacea.


Condition Intervention Phase
Acne Rosacea
Other: PRK 124
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effects of PRK 124 (0.125%) Lotion in Acne Rosacea

Resource links provided by NLM:


Further study details as provided by University of California, Irvine:

Primary Outcome Measures:
  • Erythema Severity [ Time Frame: Baseline, Weeks 1, 4, 8, 12, 24, 36, 48 ] [ Designated as safety issue: No ]
    Measured by percent improvement on a scale of 0-4. Subjects received a 0 for no improvement, 1 for less than twenty-five percent improvement, a 2 for twenty-five to fifty percent improvement, a 3 for fifty to seventy-five percent improvement and a 4 for greater than seventy-five percent improvement. Mean scores from all continuing 16 participants were averaged for each encounter, for a total of 8 visits. The percent improvement in mean erythema severity was calculated by comparing the change in mean scores at week 48 to mean scores assessed at baseline.

  • Inflammatory Lesion Count [ Time Frame: Baseline, Weeks 1, 4, 8, 12, 24, 36, 48 ] [ Designated as safety issue: No ]
    Lesion counts were numerically summed for each patient at each encounter, and the average lesion count was calculated from all continuing 16 subjects at each visit, for a total of 8 visits. Percent improvement (reduction in lesion number) was assessed by comparing the average number of lesions at week 48 to the average number of lesions assessed at baseline.

  • Telangiectasia Severity [ Time Frame: Baseline, Weeks 1, 4, 8, 12, 24, 36, 48 ] [ Designated as safety issue: No ]
    Measured by percent improvement on a scale of 0-4. Subjects received a 0 for no improvement, 1 for less than twenty-five percent improvement, a 2 for twenty-five to fifty percent improvement, a 3 for fifty to seventy-five percent improvement and a 4 for greater than seventy-five percent improvement. Mean scores from all continuing 16 participants were averaged for each encounter, for a total of 8 visits. The percent improvement in mean telangiectasia severity was calculated by comparing the change in mean scores at week 48 to mean scores assessed at baseline.


Secondary Outcome Measures:
  • Skin Tolerance [ Time Frame: Baseline, Weeks 1, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 ] [ Designated as safety issue: Yes ]
  • Skin Photodamage [ Time Frame: Baseline, Weeks 1, 4, 8, 12, 24, 36, 48 ] [ Designated as safety issue: No ]
  • Transepidermal Water Loss (TEWL) [ Time Frame: Baseline, Weeks 1, 4, 8, 12, 24, 36, 48 ] [ Designated as safety issue: No ]
  • Cosmetic Acceptability [ Time Frame: Baseline, Weeks 1, 4, 8, 12, 24, 36, 48 ] [ Designated as safety issue: No ]

Enrollment: 24
Study Start Date: April 2007
Study Completion Date: February 2009
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PRK 124
Topical PRK 124 (Pyratine-6)(0.125%) moisturizing lotion applied twice daily to the face for 48 weeks. Subjects will wash their faces prior to application. The applications will occur in the mornings and one hour before bedtime.
Other: PRK 124
Topical PRK 124 (0.125%) moisturizing lotion applied twice daily to the face for 48 weeks
Other Names:
  • Pyratine-6
  • N-furfuryl-9-(2-tetrahydropyranyl)adenine

  Hide Detailed Description

Detailed Description:

Cytokinins are plant growth factors that regulate plant growth and differentiation. PRK 124 (N-furfuryl-9-(2-tetrahydropyranyl) adenine)(Pyratine 6™) is a cytokinin that has been shown to have modulatory, anti-ROS (reactive oxygen species), and antisenescence effects on the growth of human skin cells.

Recent clinical studies showed that PRK 124 (0.1%) treatment in 40 subjects for 12 weeks improved the appearance of photodamaged facial skin by decreasing fine wrinkles, roughness and mottled hyperpigmentation. Treatment with PRK 124 lotion furthermore decreased skin transepidermal water loss and also increased skin moisture content. The topical PRK 124 lotion was well tolerated by the subjects with no significant increase in erythema or irritation. Treatment with PRK 124 was shown to decrease both acne and erythema observed at baseline.

Rosacea is a common, chronic dermatosis that is characterized by papules and pustules, persistent erythema and telangiectasia. The objective of this study is to compare the long-term efficacy and tolerance of PRK 124 (0.125%) moisturizing lotion applied twice daily for 48 weeks for improving the clinical signs and symptoms of inflammatory acne rosacea as well as cutaneous signs of skin photodamage.

Study Design:

Twenty four volunteers with mild-to-moderate facial rosacea will participate in this single center, open-label study designed to evaluate the subject=s tolerance and effectiveness of PRK 124 (0.125%) moisturizing lotion applied twice daily for 48 weeks, for improving the signs and symptoms of acne rosacea. Subjects will apply the test lotion twice daily, once in morning and again in the evening before bedtime. Subjects will be assessed at baseline and at 4, 8 and 12 weeks after treatment for improvement in the clinical signs and symptoms of acne rosacea and effect of treatments on transepidermal water loss (TEWL). In addition, the subject's tolerance will be assessed at each follow-up visit (weeks 4, 8, and 12). Facial photographs will be obtained at baseline and at 4, 8 and 12 weeks. Subjects will then be given the opportunity to continue treatment for 36 additional weeks. Subjects must have normal clinical laboratory tests, and if female, a negative urine pregnancy test at 12 weeks to continue the 36 weeks treatment. Clinical laboratory tests and urine pregnancy test will be repeated at week 48 or early study completion. Clinical assessments will be done at weeks 24, 36 and 48 during the last 36 weeks. Additional objective measures of skin moisture content and skin erythema using a chromameter will be done at week 12 and at follow-up visits (weeks 24, 36 and 48). Telephone follow-up will be done at weeks 16, 20, 28, 32 and 40 to assess subject tolerance and compliance.

Primary Study Variables:

The primary study variables are:

Observations by Investigator:

  • Inflammatory lesion count
  • Erythema and telangiectasia severity
  • Global assessment of severity
  • Overall improvement over baseline
  • Photodamage (fine wrinkles, texture, mottled hyperpigmentation)
  • Transepidermal water loss (TEWL)
  • Skin moisture content
  • Skin erythema as measured by a chromameter

Subject self assessment:

  • Signs & symptoms (burning/stinging, erythema/telangiectasia, papules/pustules)
  • Overall improvement over baseline
  • Photodamage (fine wrinkles, texture, mottled hyperpigmentation)
  • Cosmetic acceptability

The local skin tolerance of the treatments will be assessed by the Investigator and by the subject.

  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • be at least 21 years old
  • be in reasonably good health as defined by the study doctor
  • have routine laboratory tests to evaluate your blood cell count, and kidney and liver function
  • for females of child-bearing age, not be pregnant or nursing and have a negative urine pregnancy test (except if surgically sterile or at least 1 year menopausal)
  • for females, agree to use medically acceptable forms of birth control throughout the entire study (medically acceptable forms of birth control include oral contraceptive ["the pill"], implants such as Norplant®, injectable progesterone [Depo-provera®], diaphragm and spermicide or condoms and spermicide)
  • must have mild to moderate acne rosacea
  • be willing to refrain from using non-approved lotions, moisturizer, cleansers or lotions on affected facial areas during the treatment period
  • be capable of understanding and giving written, voluntary informed consent before study screening
  • be willing to consent to facial photographs at baseline and each follow-up visit to monitor treatment with the test product.

Exclusion Criteria:

  • have a history or evidence of any chronic or reoccurring skin disease or disorder (e.g., psoriasis, eczema, etc.) affecting the face
  • have known or suspected hypersensitivity to study treatment or any of its ingredients
  • have used systemic retinoids within 6 months prior to study entry (e.g., acitretin, isotretinoin)
  • have received treatment with systemic corticosteroids (e.g. prednisone) or antibiotics within 1 month
  • have used topical treatment to the face with retinoids (e.g. tretinoin, adapalene), or antibiotics or corticosteroids, within 2 weeks prior to study entry
  • are unwilling to use a sunscreen with an SPF of 30 during the study
  • have participated in any clinical trial involving an investigational drug or cosmetic product or procedure within the past 30 days
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00580723

Locations
United States, California
UC Irvine Dermatology Clinical Research Center
Irvine, California, United States, 92697
Sponsors and Collaborators
University of California, Irvine
SenetekPLC
Investigators
Principal Investigator: Gerald D Weinstein, MD University of California, Irvine
  More Information

Additional Information:
Publications:
Responsible Party: Christopher Zachary, MBBS, FRCP, University of California, Irvine
ClinicalTrials.gov Identifier: NCT00580723     History of Changes
Other Study ID Numbers: 2006-5307, Contract SPLC-41239
Study First Received: December 21, 2007
Results First Received: March 18, 2013
Last Updated: December 16, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by University of California, Irvine:
acne
rosacea
acne rosacea
papulopustular rosacea
erythema
telangiectasia
flushing

Additional relevant MeSH terms:
Rosacea
Skin Diseases

ClinicalTrials.gov processed this record on October 19, 2014